STAT+: Gossamer lung disease drug fails late-stage study, but company will still seek FDA approval

Gossamer Bio's drug for pulmonary arterial hypertension failed to achieve the primary endpoint of a Phase 3 clinical trial. Despite this outcome, the company will still seek FDA approval.